

Kwon  
10/651216

Page 1


=> dis his;d 16 que stat;d 17 que stat

(FILE 'HOME' ENTERED AT 11:06:30 ON 22 NOV 2005)

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 22 NOV 2005

L1 STR  
L2 19 S L1  
L3 STR L1  
L4 STR  
L5 2 S L4  
L6 320 S L3 FUL  
L7 57 S L5 FUL

L3 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20


STEREO ATTRIBUTES: NONE

L6 320 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 340 ITERATIONS  
SEARCH TIME: 00.00.01

320 ANSWERS

L4 STR



NODE ATTRIBUTES:

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

DEFAULT MLEVEL IS ATOM  
MLEVEL IS CLASS AT 17 18  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS UNLIMITED AT 17 18

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE  
L7 57 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 1082 ITERATIONS 57 ANSWERS  
SEARCH TIME: 00.00.01

=> fil medl,biosis,embase,capplus;s atheroscleros? or monkeberg? medical calcific  
sclerosis or arteriolosclerosis or atheroma or fatty streak(a)arterial orrestenosis  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 327.82 328.66

FILE 'MEDLINE' ENTERED AT 11:17:04 ON 22 NOV 2005

FILE 'BIOSIS' ENTERED AT 11:17:04 ON 22 NOV 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:17:04 ON 22 NOV 2005  
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPPLUS' ENTERED AT 11:17:04 ON 22 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L8 46803 FILE MEDLINE  
L9 57510 FILE BIOSIS  
L10 69191 FILE EMBASE  
L11 47306 FILE CAPPLUS

TOTAL FOR ALL FILES

L12 220810 ATHEROSCLEROS? OR MONKEBERG? MEDICAL CALCIFIC SCLEROSIS OR ARTER  
IOLOSCLEROSIS OR ATEROMA OR FATTY STREAK(A) ARTERIAL ORRESTENOS  
IS

=> del 18 y;del 19 y;del 110 y;del 111 y;del 112 y;s atheroscleros? or monkeberg?  
medical calcific sclerosis or arteriolosclerosis or atheroma or fatty  
streak(a)arterial or restenosis

L8 56335 FILE MEDLINE  
L9 68182 FILE BIOSIS  
L10 78978 FILE EMBASE  
L11 52051 FILE CAPLUS

TOTAL FOR ALL FILES

L12 255546 ATHEROSCLEROS? OR MONKEBERG? MEDICAL CALCIFIC SCLEROSIS OR ARTERIOLOSCLEROSIS OR ATHEROMA OR FATTY STREAK(A) ARTERIAL OR RESTENOSIS

=> s 16 and l12;s 17 and l12  
L13 0 FILE MEDLINE  
L14 0 FILE BIOSIS  
L15 0 FILE EMBASE  
L16 8 FILE CAPLUS

TOTAL FOR ALL FILES

L17 8 L6 AND L12

L18 0 FILE MEDLINE  
L19 0 FILE BIOSIS  
L20 0 FILE EMBASE  
L21 2 FILE CAPLUS

TOTAL FOR ALL FILES

L22 2 L7 AND L12

=> dup rem l17

PROCESSING COMPLETED FOR L17

L23 8 DUP REM L17 (0 DUPLICATES REMOVED)


=> d 1-8 ibib abs hitstr;d 122 1-2 ibib abs hitstr

L23 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:1059360 CAPLUS  
DOCUMENT NUMBER: 142:38231  
TITLE: Preparation of thienopyridine-ethanolamine derivatives as antiviral agents  
INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Eggen, Marijean; Anderson, David J.; Judge, Thomas M.; Kim, Euibong J.; Collier, Sarah A.  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
SOURCE: PCT Int. Appl., 95 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106345	A2	20041209	WO 2003-US24802	20030827
WO 2004106345	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-408067P P 20020904  
OTHER SOURCE(S): MARPAT 142:38231  
GI



I




II

AB Title compds. I [wherein R1 = Cl, Br, F or cyano; R2 = (un)substituted alkyl or (CH<sub>2</sub>)<sub>m</sub>OCH<sub>2</sub>CH<sub>2</sub>OH; R3 = C1-2 alkyl; R4 = five-membered N/O/S(O)m-heteroaryl optionally fused to benzene or pyridine ring; R5 = H or C1-2 alkyl optionally substituted with OH; m = 1 or 2, and stereoisomers or pharmaceutically acceptable salts thereof] were prepared For example, II was synthesized as a racemate in several steps. Resolution and further purification gave (R)-II isomer. This isomer showed inhibitory activity against HCMV, HSV and VZV polymerases with IC<sub>50</sub> (μM) values of 0.04, 0.09 and 0.03, resp. Therefore, I and pharmaceutical compns. thereof are useful as as herpessviral DNA polymerase inhibitors, and as antiviral agents, in particular, as agents against viruses of the herpes family.

IT 804510-51-8P 804511-05-5P, Rac-N-(4-Chlorobenzyl)-2-[[[2-hydroxy-2-(1H-pyrazol-3-yl)ethyl](methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)


RN 804510-51-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 804511-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[ (4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(1H-pyrazol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 804510-54-1P 804510-57-4P 804510-60-9P

804510-63-2P 804510-66-5P 804510-69-8P  
 804510-72-3P 804510-75-6P 804510-81-4P  
 804510-84-7P 804510-87-0P 804510-90-5P  
 804510-93-8P 804510-96-1P 804510-99-4P  
 804511-02-2P 804511-08-8P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-hydroxy-2-(1H-pyrazol-3-yl)ethyl] (methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-11-3P,  
 N-(4-Chlorobenzyl)-7-ethyl-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-14-6P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-17-9P  
 804511-20-4P 804511-23-7P 804511-29-3P  
 804511-35-1P 804511-41-9P 804511-47-5P  
 804511-50-0P 804511-57-7P 804511-66-8P  
 804511-69-1P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-4-oxo-7-propyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-78-2P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(5-chloro-2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-84-0P,  
 N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-7-(2-hydroxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-96-4P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl)amino]methyl]-7-[2-(2-hydroxyethoxy)ethyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-99-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)

RN 804510-54-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[ (4-chlorophenyl)methyl]-2-[[[(2R)-


2- (2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 804510-57-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(5-methyl-2-furanyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-60-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[2-(3-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-63-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-66-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-thienyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-69-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-72-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-75-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(1-methyl-1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-81-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-84-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(1H-indol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-87-0 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[2-(2,5-dimethyl-3-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-90-5 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzo[b]thien-3-yl-2-hydroxyethyl)methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804510-93-8 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-(1-methyl-1H-indol-2-yl)ethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-96-1 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2-(5-cyano-2-thienyl)-2-hydroxyethyl)methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-99-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(2-thiazolyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-02-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzothiazolyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-08-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(1H-pyrazol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-14-6 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 804511-23-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-29-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl-N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-35-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-41-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-47-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-50-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-57-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[2-(4,5-dimethyl-2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-66-8 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(5-phenyl-2-furanyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-69-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-78-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(5-chloro-2-furanyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-84-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-96-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-[2-(2-hydroxyethoxy)ethyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-99-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-imidazol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 292144-09-3, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 292144-10-6,  
 N-(4-Chlorobenzyl)-7-methyl-2-[(morpholin-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)


RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



IT 672326-03-3P, N-(4-Chlorobenzyl)-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-05-5P, 2-(Chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-07-7P, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[(3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-09-9P, N-(4-Chlorobenzyl)-2-(chloromethyl)-4-oxo-7-[(3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-11-3P, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[(3-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-12-4P, N-(4-Chlorobenzyl)-2-


(chloromethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-13-5P**,  
N-(4-Chlorobenzyl)-2-(chloromethyl)-7-(2-hydroxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-15-7P**,  
N-(4-Chlorobenzyl)-7-ethyl-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-17-9P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-ethyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-18-0P**, N-(4-Chlorobenzyl)-7-propyl-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-20-4P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-propyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-22-6P**,  
N-(4-Chlorobenzyl)-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-23-7P**,  
N-(4-Chlorobenzyl)-2-(chloromethyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672949-78-9P**,  
N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672949-80-3P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **804510-78-9P** **804511-26-0P**  
**804511-32-8P** **804511-38-4P** **804511-44-2P**  
**804511-81-7P** **804511-93-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)


RN **672326-03-3** CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN **672326-05-5** CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-15-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-23-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-78-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672949-80-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 804510-78-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-[1-(triphenylmethyl)-1H-imidazol-4-yl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-26-0 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-32-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-38-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[3-(tetrahydro-2H-pyran-2-yl)oxy]propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-44-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl)methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[(3-(tetrahydro-2H-pyran-2-yl)oxy)propyl]- (9CI) (CA INDEX NAME)



RN 804511-81-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl)methylamino]methyl]-4,7-dihydro-4-oxo-7-[(2-(tetrahydro-2H-pyran-2-yl)oxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-93-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 672326-01-1P, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of (hydroxyethylamino)methyl dihydrothienopyridines as antiviral agents)


RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



L23 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:220341 CAPLUS  
 DOCUMENT NUMBER: 140:270842  
 TITLE: Preparation of arylethanol(thienopyridinemethyl)amine derivatives as antiviral agents  
 INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Ciske, Fred L.; Genin, Michael J.; Anderson, David J.; Judge, Thomas M.; Eggen, Marijean; Collier, Sarah A.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022568	A1	20040318	WO 2003-US24807	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004116464	A1	20040617	US 2003-649202	20030827
US 2005049245	A1	20050303	US 2003-649208	20030827
PRIORITY APPLN. INFO.:			US 2002-408206P	P 20020904
OTHER SOURCE(S):	MARPAT 140:270842			
GI				



AB Arylethanol (thienopyridinemethyl)amine derivs. of formula I [R1 = halo, CN; R2 = (substituted) alkyl, etc.; R3 = alkyl; R4 = H, (substituted) alkyl; Ar = (substituted) Ph, aryl] are prepared as antiviral agents, in particular, as agents against viruses of the herpes family. Thus, II was prepared, and had IC50 of 0.05  $\mu$ M against HCMV polymerase.


IT 672325-77-8P 672325-86-9P 672325-93-8P  
672325-95-0P 672325-97-2P 672325-98-3P  
672325-99-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of arylethanol (thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-77-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-86-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-93-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-95-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-97-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-98-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-[(4-hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-99-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 672325-79-0P 672325-81-4P 672325-82-5P

672325-84-7P 672325-88-1P 672325-90-5P

672325-91-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-79-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-81-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-82-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672325-84-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2S)-2-hydroxy-2-

phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 672325-88-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-(9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 672325-90-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 672325-91-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

## Absolute stereochemistry. Rotation (+).




IT 292144-13-9

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-38-4P 672326-39-5P 672326-40-8P

672326-41-9P 672326-42-0P 672326-43-1P

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)  
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)


RN 672326-38-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-39-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-40-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 672326-41-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 672326-42-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-[4-(hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OH

RN 672326-43-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 292144-09-3 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)


RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-01-1P 672326-03-3P 672326-05-5P  
672326-07-7P 672326-09-9P 672326-11-3P  
672326-12-4P 672326-13-5P 672326-15-7P  
672326-17-9P 672326-18-0P 672326-20-4P  
672326-22-6P 672326-23-7P 672326-26-0P  
672326-28-2P 672326-29-3P 672326-30-6P  
672326-32-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)


RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-03-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-15-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-23-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-26-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672326-28-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[(3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672326-29-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672326-30-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-32-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[2-[4-(dimethylamino)phenyl]-2-oxoethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L23 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220340 CAPLUS

DOCUMENT NUMBER: 140:270841

TITLE: Preparation of heteroarylethanolamines as antiviral agents  
 INVENTOR(S): Fleck, Thomas J.; Schnute, Mark E.; Cudahy, Michele M.; Anderson, David J.; Judge, Thomas M.; Herrington, Paul M.; Nair, Sajiv K.; Scott, Allen; Perrault, William R.; Tanis, Steven P.; Nieman, James A.; Collier, Sarah A.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA; Fleck, Bruce Francis  
 SOURCE: PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022567	A1	20040318	WO 2003-US24806	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110787	A1	20040610	US 2003-649301	20030827
US 2002-408065P P 20020904				
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 140:270841				
GI				



AB Title compds. [I; R1 = Cl, Br, F, cyano; R2 = alkyl, hydroxyalkyl, alkoxyalkyl,  $(\text{CH}_2)_m\text{OCH}_2\text{CH}_2\text{OH}$ ; m = 1, 2; R3 = alkyl; R4 = (R6-substituted) (benzo-fused) C-bonded 6-membered heteroaryl containing 1-3 N atoms; R5 = H, alkyl, hydroxyalkyl; R6 = halo, OCF3, cyano, NO2, CONR7R8, NR7R8, OR10, CO2R10, (unsatd.) (R9-substituted) alkyl, etc.; R7, R8 = H, (substituted) Ph, alkyl, cycloalkyl, etc.; R9 = O, OR10, SR10, halo, NR7R8, CO2R10, etc.; R10 = H, alkyl, cycloalkyl, (substituted) Ph], were prepared. Thus, N-(4-chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (preparation given), diisopropylethylamine, and 2-(methylamino)-1-pyridin-3-ylethanol hydrobromide were heated in DMF at 90° for 2 h to give N-(4-chlorobenzyl)-2-[(2-hydroxy-2-pyridin-3-ylethyl)(methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide. The latter inhibited HCMV, HSV, and VSV polymerase with IC50 = 0.16, 0.58, and 0.22  $\mu\text{M}$ , resp.

IT 672949-14-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(preparation of heteroarylethanolamines as antiviral agents)

RN 672949-14-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




IT 672949-12-1P 672949-16-5P 672949-18-7P  
672949-20-1P 672949-22-3P 672949-24-5P  
672949-26-7P 672949-28-9P 672949-30-3P  
672949-32-5P 672949-34-7P 672949-36-9P  
672949-38-1P 672949-40-5P 672949-42-7P  
672949-44-9P 672949-46-1P 672949-48-3P  
672949-50-7P 672949-52-9P 672949-54-1P  
672949-57-4P 672949-59-6P 672949-61-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylethanolamines as antiviral agents)


RN 672949-12-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-16-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(4-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-18-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-20-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 672949-22-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(6-methyl-2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-24-5 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(2-quinolinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-26-7 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-28-9 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2R]-2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-30-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-32-5 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672949-34-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-(3-pyridazinyl)ethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-36-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo-(9CI) (CA INDEX NAME)




RN 672949-38-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[(2-hydroxy-2-(2-pyridinyl)ethyl)methylamino]methyl]-4-oxo-(9CI) (CA INDEX NAME)




RN 672949-40-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[(2-hydroxy-2-(2-pyridinyl)ethyl)methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-42-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-44-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-46-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-48-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-7- (3-hydroxypropyl) -2- [[[2-hydroxy-2- (2-pyrimidinyl)ethyl]methylamino]methyl] -4-oxo- (9CI) (CA INDEX NAME)



RN 672949-50-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7- (2-hydroxyethyl) -2- [[[2R]-2-hydroxy-2- (2-pyridinyl)ethyl]methylamino]methyl] -4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-52-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2- [(2-hydroxy-2-pyrazinylethyl)methylamino]methyl] -7- (2-methoxyethyl) -4-oxo- (9CI) (CA INDEX NAME)



RN 672949-54-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7- [2-(2-hydroxyethoxy)ethyl] -2- [[[2R]-2-hydroxy-2- (2-pyrazinylethyl)methylamino]methyl] -4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-57-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


### Absolute stereochemistry. Rotation (+).



RN 672949-59-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


## Absolute stereochemistry. Rotation (+).



RN 672949-61-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




IT 292144-09-3 292144-10-6 672950-41-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heteroarylethanolamines as antiviral agents)


RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672950-41-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(dimethylamino)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-01-1P 672326-03-3P 672326-05-5P  
672326-07-7P 672326-09-9P 672326-11-3P  
672326-12-4P 672326-13-5P 672326-15-7P  
672326-17-9P 672326-18-0P 672326-20-4P  
672326-22-6P 672326-23-7P 672326-30-6P  
672949-78-9P 672949-80-3P 672950-21-9P  
672950-23-1P 672950-25-3P 672950-27-5P  
672950-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroarylethanolamines as antiviral agents)


RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-03-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-15-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-23-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-30-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-78-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 672949-80-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-

chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 672950-21-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[[methyl(2-oxo-2-pyrazinylethyl)amino]methyl]-4-oxo-(9CI) (CA INDEX NAME)



RN 672950-23-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672950-25-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672950-27-5 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 672950-29-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo-7-[2-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203665 CAPLUS

DOCUMENT NUMBER: 140:229446

TITLE: Method using heterocyclic carboxamide compounds for preventing or treating atherosclerosis or restenosis

INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004102473	A1	20040527	US 2003-651216	20030828

PRIORITY APPLN. INFO.: US 2002-407090P P 20020830

OTHER SOURCE(S): MARPAT 140:229446


AB The invention provides a method of treating **atherosclerosis** or **restenosis** in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-ij]quinoline carboxamide derivative

IT 292143-70-5 292143-71-6 292143-72-7  
 292143-74-9 292143-76-1 292143-78-3  
 292143-79-4 292143-83-0 292143-85-2  
 292143-86-3 292143-90-9 292143-92-1  
 292143-94-3 292143-96-5 292143-98-7  
 292144-00-4 292144-02-6 292144-04-8  
 292144-06-0 292144-09-3 292144-10-6  
 292144-12-8 292144-13-9 292144-14-0  
 292144-16-2 292144-17-3 292144-18-4  
 292144-19-5 292144-20-8 292144-22-0  
 292144-23-1 292144-24-2 292144-25-3  
 292144-26-4 292144-27-5 292144-28-6  
 292144-29-7 292144-30-0 292144-31-1  
 292144-32-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heterocyclic carboxamide compds. for preventing or treating **atherosclerosis** or **restenosis**)


RN 292143-70-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-bromo-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-71-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-72-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-iodo-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-74-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-76-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxy-1-butynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-78-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-79-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-83-0 CAPLUS

CN Thieno[2,3-b]pyridine-7(4H)-acetic acid, 5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-85-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxybutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-86-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-90-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-iodo-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-92-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-94-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-96-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-iodo-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-98-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-00-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-02-6 CAPLUS

CN Butanedioic acid, mono[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI)  
(CA INDEX NAME)



RN 292144-04-8 CAPLUS


CN 4-Morpholineacetic acid, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI)  
(CA INDEX NAME)




RN 292144-06-0 CAPLUS

CN Benzoic acid, 3-(4-morpholinylmethyl)-, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-12-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo-2-(4-thiomorpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-14-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-16-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-17-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 292144-18-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(1-methylethyl)-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-19-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-20-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-22-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylcarbonyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-23-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-24-2 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(3-fluorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-25-3 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 292144-26-4 CAPLUS  
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 292144-27-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 292144-28-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-29-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-30-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-31-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-32-2 CAPLUS

CN L-Valine, 3-[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L23 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:203660 CAPLUS  
 DOCUMENT NUMBER: 140:229445  
 TITLE: Method using heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis  
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 190 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019933	A1	20040311	WO 2003-US26963	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004176366	A1	20040909	US 2003-651290	20030828
PRIORITY APPLN. INFO.:			US 2002-407563P	P 20020830
			US 2003-469630P	P 20030509


OTHER SOURCE(S): MARPAT 140:229445  
 AB The invention provides a method of preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.  
 IT 292144-10-6 292144-14-0 292144-20-8  
 RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis)  
 RN 292144-10-6 CAPLUS  
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-14-0 CAPLUS  
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 292144-20-8 CAPLUS  
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:202648 CAPLUS  
 DOCUMENT NUMBER: 138:238160  
 TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents  
 INVENTOR(S): Thorarensen, Atli  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
WO 2003020730	A1	20030313	WO 2002-US27738	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452438	AA	20030313	CA 2002-2452438	20020829
US 2003100536	A1	20030529	US 2002-230891	20020829
US 6924283	B2	20050802		
EP 1421088	A1	20040526	EP 2002-757510	20020829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011557	A	20040713	BR 2002-11557	20020829
JP 2005502686	T2	20050127	JP 2003-525000	20020829
PRIORITY APPLN. INFO.:			US 2001-316129P	P 20010830
			WO 2002-US27738	W 20020829

OTHER SOURCE(S): MARPAT 138:238160  
GI



I



II

AB The title compds. [I; R1 = Cl, Br, CN, NO<sub>2</sub>, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, **atherosclerosis** or **restenosis**, were prepared. Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC<sub>50</sub> of 0.91  $\mu$ M, 0.36  $\mu$ M and 0.13  $\mu$ M against HCMV, HSV and VZV polymerases, resp.


IT 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides

as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202647 CAPLUS

DOCUMENT NUMBER: 138:238159

TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents

INVENTOR(S): Thorarensen, Atli

PATENT ASSIGNEE(S): Pharmacia &amp; Upjohn Company, USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020729	A1	20030313	WO 2002-US27527	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452431	AA	20030313	CA 2002-2452431	20020829
US 2003109542	A1	20030612	US 2002-230890	20020829
US 6620810	B2	20030916		
EP 1421089	A1	20040526	EP 2002-763566	20020829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011214	A	20040713	BR 2002-11214	20020829
JP 2005502685	T2	20050127	JP 2003-524999	20020829
PRIORITY APPLN. INFO.:			US 2001-316108P	P 20010830
			WO 2002-US27527	W 20020829
OTHER SOURCE(S):	MARPAT	138:238159		
GI				



I



II

AB The title compds. [I; R1 = Cl, Br, CN, NO<sub>2</sub>, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, **atherosclerosis** or **restenosis**, were prepared. Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded 37% I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC<sub>50</sub> of 0.63  $\mu$ M, 0.16  $\mu$ M and 0.08  $\mu$ M against HCMV, HSV and VZV polymerases, resp.


IT 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202646 CAPLUS

DOCUMENT NUMBER: 138:238158


TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents

INVENTOR(S): Thorarensen, Atli


PATENT ASSIGNEE(S) : Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020728	A1	20030313	WO 2002-US25858	20020814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003100536	A1	20030529	US 2002-230891	20020829
US 6924283	B2	20050802	US 2001-316129P	P 20010830

PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S) : MARPAT 138:238158  
 GI



I



II


AB The title compds. [I; R1 = Cl, Br, CN, NO<sub>2</sub>, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, atherosclerosis or restenosis, were prepared. Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC<sub>50</sub> of 0.91 μM, 0.36 μM and 0.13 μM against HCMV, HSV and VZV polymerases, resp.

IT 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:203665 CAPLUS  
 DOCUMENT NUMBER: 140:229446  
 TITLE: Method using heterocyclic carboxamide compounds for preventing or treating **atherosclerosis** or **restenosis**  
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 110 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004102473	A1	20040527	US 2003-651216	20030828
PRIORITY APPLN. INFO.:			US 2002-407090P	P 20020830
OTHER SOURCE(S):	MARPAT	140:229446		
AB	The invention provides a method of treating <b>atherosclerosis</b> or <b>restenosis</b> in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-ij]quinoline carboxamide derivative			
IT	388121-63-9 388121-67-3 388121-74-2			


388121-75-3 388121-76-4 388121-77-5  
388121-78-6 388121-79-7 388121-80-0  
388121-81-1 388121-82-2 388121-85-5  
388121-86-6 388121-87-7 388121-88-8  
388121-89-9 388121-93-5 388121-94-6  
388121-95-7 388121-96-8 388121-97-9  
388121-98-0 388121-99-1 388122-00-7  
388122-01-8 388122-02-9 388122-03-0  
388122-04-1 388122-05-2 388122-06-3  
388122-07-4 388122-08-5 388122-09-6  
388122-10-9 388122-11-0 388122-12-1  
388122-13-2 388122-14-3 388122-15-4  
388122-16-5 388122-17-6 388122-18-7  
388122-20-1 388122-21-2 388122-22-3  
388122-23-4 388122-24-5 388122-25-6  
388122-26-7 388122-27-8 388122-28-9  
388122-29-0 388122-30-3 388122-31-4  
388122-32-5 388122-33-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heterocyclic carboxamide compds. for preventing or treating atherosclerosis or restenosis)


RN 388121-63-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-67-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-6-oxo-8-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 388121-74-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-75-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-76-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(4-morpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-77-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(diethylamino)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-78-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(4-methyl-1-piperazinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)  
(CA INDEX NAME)




RN 388121-79-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(2-ethyl-1-piperidinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-80-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[3-(4-methyl-1-piperazinyl)propyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)  
(CA INDEX NAME)




RN 388121-81-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 388121-82-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-2-[3-(4-morpholinyl)propyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-85-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-86-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-1-iodo-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-87-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(3-hydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388121-88-8 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 2-[(aminocarbonyl)amino]methyl-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388121-89-9 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1R)-1-hydroxyethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388121-93-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(methoxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-94-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(ethylthio)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-95-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 388121-96-8 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(methylamino)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-97-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(dimethylamino)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-98-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-99-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-6-oxo-8-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 388122-00-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-hydroxy-1-(hydroxymethyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-01-8 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[1,2-dihydroxy-1-(hydroxymethyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-02-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(ethylsulfonyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-03-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(ethylsulfinyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-04-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 2-[[bis(2-hydroxyethyl)amino]methyl]-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-05-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(2-hydroxyethoxy)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-06-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(1,2-dihydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-07-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-(1,2,3-trihydroxypropyl)- (9CI) (CA INDEX NAME)




RN 388122-08-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[3-hydroxy-2-(hydroxymethyl)propyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)  
(CA INDEX NAME)




RN 388122-09-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-10-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(2-hydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-11-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-12-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(4-morpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-13-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-14-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-15-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(4-methyl-1-piperazinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-16-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 388122-17-6 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 1-[(acetylamino)methyl]-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388122-18-7 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[(1S)-1-hydroxyethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388122-20-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(1H-imidazol-1-ylmethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-21-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 1-(1H-benzotriazol-1-ylmethyl)-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)  
(CA INDEX NAME)




RN 388122-22-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 388122-23-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 388122-24-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(3-oxo-1-azetidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-25-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(3-hydroxy-1-azetidinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388122-26-7 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2,3-dihydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388122-27-8 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1S)-1-hydroxyethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388122-28-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(1H-imidazol-1-yl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-29-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(1H-imidazol-2-yl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-30-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1H-1,2,4-triazol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-31-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-32-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 388122-33-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[5-[(4-chlorophenyl)methyl]amino]carboxyl]-8-(4-morpholinylmethyl)-6-oxo-6H-pyrrolo[3,2,1-ij]quinolin-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:203660 CAPLUS  
 DOCUMENT NUMBER: 140:229445  
 TITLE: Method using heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**  
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 190 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019933	A1	20040311	WO 2003-US26963	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004176366	A1	20040909	US 2003-651290	20030828
PRIORITY APPLN. INFO.:			US 2002-407563P	P 20020830
			US 2003-469630P	P 20030509

OTHER SOURCE(S): MARPAT 140:229445  
 AB The invention provides a method of preventing or treating **atherosclerosis** or **restenosis** in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.  
 IT 388121-74-2  
 RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**)  
 RN 388121-74-2 CAPLUS  
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-

(hydroxymethyl) - 8 - (4 - morpholinylmethyl) - 6 - oxo - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 11:06:30 ON 22 NOV 2005)

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 22 NOV 2005

L1				STR
L2			19	S L1
L3				STR L1
L4				STR
L5		2	S L4	
L6	320	S L3	FUL	
L7	57	S L5	FUL	

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 11:17:04 ON 22 NOV 2005

L8 56335 FILE MEDLINE  
L9 68182 FILE BIOSIS  
L10 78978 FILE EMBASE  
L11 52051 FILE CAPLUS  
TOTAL FOR ALL FILES

TOTAL FOR ALL FILES

0 ETILE MEDLINE

0 FILE MEDLINE  
0 FILE BIOSIS

BT4 0 FILE BIOSIS  
BT5 0 FILE EMBASE

0 FILE EMBASSY  
8 FILE CARLIS

8 FILE CAP.

**TOTAL FOR ALL FILES**

83 E8 AND E12  
0 FILE MEDIUM

L18 0 FILE MEDLINE  
L18 0 FILE BIOSIS

0 FILE BIOSIS  
0 FILE EMBASE

3 FILE END

2 FILE CAPTION  
TOTAL: FOR ALL FILES

**TOTAL FOR ALL FILES**

2 5 E, AND 81  
8 DUP REM 112


B25 8 DOF KEM ST.

→ d 16 wie stat:d 17 wie st

13 STR

L3

## 25. DR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20


STEREO ATTRIBUTES: NONE

L6 320 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 340 ITERATIONS  
SEARCH TIME: 00.00.01

320 ANSWERS

L4 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
MLEVEL IS CLASS AT 17 18  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS UNLIMITED AT 17 18

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L7 57 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 1082 ITERATIONS  
SEARCH TIME: 00.00.01

57 ANSWERS

=> log y  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	117.50	446.16

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-7.30	-7.30

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:19:51 ON 22 NOV 2005